Dr Reddy's Laboratories' Q2 net profit soars 77% to Rs 504 cr; revenue up 7% to Rs 3,798 cr
Commenting on the results, Dr Reddy's Lab's co-chairman and CEO, G V Prasad said, "I am encouraged by our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results.


Representational pic. GettyImages[/caption]On the results, Co-chairman and CEO, G V Prasad said, "I am encouraged by our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results. Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable affordable medicines for more patients." Revenues from Global Generics segment in the Q2 was reported at Rs 3,050 crore a year-on-year growth of 7 percent over the same quarter last year, primarily driven by contributions from Emerging Markets, India and favorable forex. Revenues from Pharmaceutical Services and Active Ingredients was at Rs 600 crore in the second quarter with seven percent growth over the Q2 of FY18.

South Korea economy grows faster than expected in Q2 as chip exports power recovery
India remains among fastest-growing major economies despite global uncertainty, says RBI Bulletin
Iran war could cut global growth by more than half: World Bank’s chief economist Indermit Gill
Brent crude climbs to $94 as analysts expect oil prices to stay in $90–100 range
UK inflation cools further to 2.6% in June as transport and food prices ease

